PMID- 18067823
OWN - NLM
STAT- MEDLINE
DCOM- 20080630
LR  - 20151119
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 87
IP  - 36
DP  - 2007 Sep 25
TI  - [Surface enhanced laser desorption/ionization time-of-flight mass spectrometry 
      profiling of serum in detection of laryngeal squamous cell carcinoma and the 
      progression to lymph node metastasis].
PG  - 2526-30
AB  - OBJECTIVE: To assess the use of surface enhanced laser desorption/ionization 
      time-of-flight mass spectrometry (SELDI-TOF MS) to identify multiple serum 
      protein biomarkers for early detection of laryngeal squamous cell carcinoma 
      (LSCC), to establish predictive model, and to accurately distinguish LSCC 
      patients with or without lymph node metastasis. METHODS: Serum samples were 
      collected from 142 LSCC patients and 110 normal controls, totally 252, and 
      randomly divided into 2 groups: model establishment group (including 89 patients 
      with LSCC at the stages I and II, 30 of which had lymph node metastasis, and 65 
      normal controls) and blind test group (including 53 patients with LSCC at the 
      stages III and IV and 45 normal controls). Serum protein profiling on weak 
      cationic exchange (WCX2) was performed by SELDI-TOF MS and the results were 
      analyzed by Biomarker Wizard software. The Decision Tree classification algorithm 
      and blind validation were determined by Biomarker Pattern software (BPS). 
      RESULTS: A panel of 18 biomarkers ranging from 2,000 to 50,000 was selected based 
      on their collective contribution to the optimal separation between the LSCC 
      patients and healthy controls. Among them 1 candidate protein peak with the M/Z 
      value of 4,176 was selected to establish predictive model by BPS with the 
      sensitivity of 86.52% and the specificity of 84.62%. The ability to detect LSCC 
      patients was evaluated using blind test data in cancer patients. The sensitivity 
      of the blind test was 84.91%, and the specificity was 82.22%. 14 potential 
      biomarkers were found to differentiate the LSCC patients with or without lymph 
      node metastasis (P < 0.05). CONCLUSION: The high sensitivity and specificity 
      achieved by the serum protein biomarkers show great potential for the early 
      detection of LSCC. SELDI-TOF MS serum profiling is able to distinguish LSCC 
      patients with or without lymph node metastasis.
FAU - Cheng, Lei
AU  - Cheng L
AD  - Department of Otolaryngology-Head and Neck Surgery, Fudan University Affiliated 
      Eye, Ear, Nose and Throat Hospital, Shanghai 200031, China.
FAU - Zhou, Liang
AU  - Zhou L
FAU - Tao, Lei
AU  - Tao L
FAU - Zhang, Ming
AU  - Zhang M
FAU - Cui, Jie-Feng
AU  - Cui JF
FAU - Liu, Yin-Kun
AU  - Liu YK
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Blood Proteins)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Blood Proteins/*analysis
MH  - Carcinoma, Squamous Cell/blood/*pathology
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/blood/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/*methods
EDAT- 2007/12/11 09:00
MHDA- 2008/07/01 09:00
CRDT- 2007/12/11 09:00
PHST- 2007/12/11 09:00 [pubmed]
PHST- 2008/07/01 09:00 [medline]
PHST- 2007/12/11 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2007 Sep 25;87(36):2526-30.